Remove Document Remove FDA Remove Sterile Compounds
article thumbnail

Out of Shortage, Into Controversy: The Fight Over GLP-1 Compounding

Pharmacy Times

Rumore, PharmD, Esq, MS, LLM, FAPhA Key Takeaways The removal of tirzepatide and semaglutide from the FDA's shortage list impacts 503A compounders, requiring adherence to complex legal and regulatory frameworks. SHOW MORE GLP-1 compounding faces legal challenges, evolving FDA rules, and heightened enforcement risks.

article thumbnail

Advocates for Safe IV Preparation Practices Share Their Inspiration Podcast

Omnicell

In fact, in a 2020 ISMP Sterile Compounding Pulse Check conducted with 634 pharmacy practitioners, only 25% of respondents report using technologies that include barcode verification, images, and gravimetric verification for 50% of compounded sterile products. .